Q1 Earnings Forecast for TNYA Issued By HC Wainwright

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Tenaya Therapeutics in a report released on Tuesday, March 11th. HC Wainwright analyst J. Pantginis expects that the company will post earnings per share of ($0.14) for the quarter. HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Tenaya Therapeutics’ Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.59) EPS, FY2026 earnings at ($0.56) EPS, FY2027 earnings at ($0.51) EPS and FY2028 earnings at ($0.58) EPS.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its earnings results on Monday, March 17th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04.

TNYA has been the subject of a number of other research reports. Chardan Capital reduced their price objective on Tenaya Therapeutics from $18.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday. Morgan Stanley reduced their price objective on Tenaya Therapeutics from $15.00 to $5.00 and set an “overweight” rating for the company in a research note on Wednesday. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $8.75.

Tenaya Therapeutics Price Performance

Shares of TNYA stock opened at $0.60 on Thursday. The firm has a market capitalization of $47.56 million, a price-to-earnings ratio of -0.42 and a beta of 2.83. The business has a fifty day moving average of $1.09 and a 200 day moving average of $1.84. Tenaya Therapeutics has a 1 year low of $0.39 and a 1 year high of $5.55.

Insider Buying and Selling at Tenaya Therapeutics

In other Tenaya Therapeutics news, major shareholder Group Gp Lp Column III bought 35,714,284 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were purchased at an average cost of $0.70 per share, for a total transaction of $24,999,998.80. Following the transaction, the insider now directly owns 49,313,559 shares of the company’s stock, valued at approximately $34,519,491.30. The trade was a 262.62 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last quarter, insiders sold 19,621 shares of company stock worth $10,595. Insiders own 32.76% of the company’s stock.

Institutional Investors Weigh In On Tenaya Therapeutics

A number of institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. grew its position in shares of Tenaya Therapeutics by 20,670.3% during the 4th quarter. JPMorgan Chase & Co. now owns 5,155,596 shares of the company’s stock valued at $7,373,000 after acquiring an additional 5,130,774 shares during the period. FMR LLC grew its position in shares of Tenaya Therapeutics by 1.9% during the 3rd quarter. FMR LLC now owns 1,345,938 shares of the company’s stock valued at $2,598,000 after acquiring an additional 25,503 shares during the period. Geode Capital Management LLC grew its position in shares of Tenaya Therapeutics by 5.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,296,156 shares of the company’s stock valued at $2,502,000 after acquiring an additional 66,968 shares during the period. State Street Corp grew its position in shares of Tenaya Therapeutics by 0.9% during the 3rd quarter. State Street Corp now owns 1,058,898 shares of the company’s stock valued at $2,044,000 after acquiring an additional 9,506 shares during the period. Finally, abrdn plc boosted its holdings in Tenaya Therapeutics by 9.1% in the 4th quarter. abrdn plc now owns 600,700 shares of the company’s stock worth $859,000 after buying an additional 50,000 shares during the last quarter. 90.54% of the stock is currently owned by institutional investors and hedge funds.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.